Beta-amyloid is a protein fragment that accumulates abnormally in the brains of people with Alzheimer's disease. It is derived from a larger protein called amyloid precursor protein (APP). In Alzheimer's, beta-amyloid clumps together to form plaques, which disrupt communication between brain cells and contribute to their gradual dysfunction and death. This accumulation is believed to be one of the primary causes of Alzheimer's disease, leading to the characteristic symptoms of memory loss, cognitive decline, and behavioral changes.
Research suggests that beta-amyloid plaques may trigger a cascade of events, including inflammation and the formation of tangles of another protein called tau, which further damage and kill neurons. Understanding beta-amyloid's role is crucial for developing effective treatments to halt or slow the progression of Alzheimer's disease and related dementias. Current efforts focus on developing drugs that target beta-amyloid, as well as exploring preventive strategies and diagnostic tools to detect its presence early in the disease process.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States